vs
Side-by-side financial comparison of BXP, Inc. (BXP) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $872.1M, roughly 1.4× BXP, Inc.). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 15.3%, a 1.7% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 0.8%). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 1.3%).
BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
BXP vs JAZZ — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $872.1M | $1.2B |
| Net Profit | $133.0M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | — | 21.2% |
| Net Margin | 15.3% | 17.0% |
| Revenue YoY | 0.8% | 10.1% |
| Net Profit YoY | 53.0% | 6.5% |
| EPS (diluted) | $1.69 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $1.2B | ||
| Q3 25 | $871.5M | $1.1B | ||
| Q2 25 | $868.5M | $1.0B | ||
| Q1 25 | $865.2M | $897.8M | ||
| Q4 24 | $858.6M | $1.1B | ||
| Q3 24 | $859.2M | $1.1B | ||
| Q2 24 | $850.5M | $1.0B |
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $203.5M | ||
| Q3 25 | $-121.7M | $251.4M | ||
| Q2 25 | $89.0M | $-718.5M | ||
| Q1 25 | $61.2M | $-92.5M | ||
| Q4 24 | $-228.9M | $191.1M | ||
| Q3 24 | $83.6M | $215.1M | ||
| Q2 24 | $79.6M | $168.6M |
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | — | ||
| Q3 25 | 59.3% | — | ||
| Q2 25 | 59.2% | — | ||
| Q1 25 | 59.2% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 59.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -65.6% | ||
| Q1 25 | — | -6.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 19.5% |
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 17.0% | ||
| Q3 25 | -14.0% | 22.3% | ||
| Q2 25 | 10.2% | -68.7% | ||
| Q1 25 | 7.1% | -10.3% | ||
| Q4 24 | -26.7% | 17.6% | ||
| Q3 24 | 9.7% | 20.4% | ||
| Q2 24 | 9.4% | 16.5% |
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $3.34 | ||
| Q3 25 | $-0.77 | $4.08 | ||
| Q2 25 | $0.56 | $-11.74 | ||
| Q1 25 | $0.39 | $-1.52 | ||
| Q4 24 | $-1.46 | $2.97 | ||
| Q3 24 | $0.53 | $3.42 | ||
| Q2 24 | $0.51 | $2.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $512.8M | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | $7.7B | $4.3B |
| Total Assets | $25.1B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $861.1M | $1.3B | ||
| Q2 25 | $447.0M | $1.2B | ||
| Q1 25 | $398.1M | $1.9B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $685.4M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B |
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $4.3B | ||
| Q3 25 | $5.0B | $4.0B | ||
| Q2 25 | $5.3B | $3.7B | ||
| Q1 25 | $5.3B | $4.2B | ||
| Q4 24 | $5.4B | $4.1B | ||
| Q3 24 | $5.8B | $4.2B | ||
| Q2 24 | $5.8B | $3.8B |
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $11.7B | ||
| Q3 25 | $26.0B | $11.4B | ||
| Q2 25 | $25.6B | $10.9B | ||
| Q1 25 | $25.4B | $11.5B | ||
| Q4 24 | $26.1B | $12.0B | ||
| Q3 24 | $26.4B | $12.3B | ||
| Q2 24 | $25.5B | $11.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $362.5M |
| Free Cash FlowOCF − Capex | — | $345.8M |
| FCF MarginFCF / Revenue | — | 28.9% |
| Capex IntensityCapex / Revenue | 1.5% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $362.5M | ||
| Q3 25 | $274.2M | $474.6M | ||
| Q2 25 | $353.1M | $88.9M | ||
| Q1 25 | $210.0M | $429.8M | ||
| Q4 24 | $383.7M | $398.6M | ||
| Q3 24 | $286.1M | $398.7M | ||
| Q2 24 | $367.1M | $331.4M |
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $345.8M | ||
| Q3 25 | $231.6M | $459.4M | ||
| Q2 25 | $281.5M | $75.9M | ||
| Q1 25 | $152.6M | $415.9M | ||
| Q4 24 | $312.5M | $385.3M | ||
| Q3 24 | $234.5M | $388.0M | ||
| Q2 24 | $332.4M | $324.3M |
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 28.9% | ||
| Q3 25 | 26.6% | 40.8% | ||
| Q2 25 | 32.4% | 7.3% | ||
| Q1 25 | 17.6% | 46.3% | ||
| Q4 24 | 36.4% | 35.4% | ||
| Q3 24 | 27.3% | 36.8% | ||
| Q2 24 | 39.1% | 31.7% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 1.4% | ||
| Q3 25 | 4.9% | 1.3% | ||
| Q2 25 | 8.2% | 1.2% | ||
| Q1 25 | 6.6% | 1.5% | ||
| Q4 24 | 8.3% | 1.2% | ||
| Q3 24 | 6.0% | 1.0% | ||
| Q2 24 | 4.1% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.78× | ||
| Q3 25 | — | 1.89× | ||
| Q2 25 | 3.97× | — | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | 3.42× | 1.85× | ||
| Q2 24 | 4.61× | 1.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
